Favipiravi (T-705)

Description

Favipiravir (T**5) shows antiviral activity by inhibiting RNA polymerases associated with influenza virus replication. Preclinical pharmacophilic sinology shows that it is not only resistant to seasonal influenza viruses, but also to various influenza viruses of pig origin and highly pathogenic avian influenza, and no significant cross-resistance to existing drug-resistant cell strains; It is effective against a variety of subtype avian influenza viruses, such as H1N1, H5N1 and H7N9, as well as the transcription of other viruses, such as sand-grain virus, yellow fever virus, West Nile disease, bubonia virus and hand-foot-mouth virus, as well as the replication of Zaire-type Ebola virus RNA (IC*0 **0 mol/L). Therefore, it is a new antiviral drug with accurate efficacy and good safety mechanism, and has good application prospect.